Releases
25. October, 2023
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children
The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number...
Releases
21. September, 2023
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001
Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of...
Releases
12. September, 2023
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children
On 12 September – Cessatech A/S (“Cessatech” or “the Company”) announces that EMA’s Paediatric...
Releases
24. August, 2023
Second quarter report Q2-2023
US co-development and commercialization partnership signed for CT001 – potential income already from 2024...
Releases
27. June, 2023
Cessatech and Ventis Pharma announce US partnership for CT001
On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...
Releases
12. May, 2023
First quarter report Q1-2023 with Q&A
First quarter report Q1-2023 Study 0205 is progressing, with last patient expected in Q3...
Releases
23. March, 2023
Cessatech announces new Chairman of the Board
On 23 March 2023 Cessatech A/S announces that the Board of Directors has appointed...
Releases
28. February, 2023
Annual Report for the fiscal year 2022
Cessatech today publishes its annual report for the fiscal year 2022, which also includes...
Releases
18. November, 2022
Third quarter report Q3-2022
Cessatech today releases its results for the period 1 July – 30 September 2022....
Releases
14. November, 2022
Successful outcome of Rights issue
The results of the rights issue announced on October 19, 2022 for which the...
Releases
19. October, 2022
DKK 18.3 million capital raise through a 80% guarantee
DKK 18.3 MILLION CAPITAL RAISE THROUGH A 80% GUARANTEED RIGHTS ISSUE TO FINANCE PIVOTAL...
Releases
23. September, 2022
Successful outcome of pharmacokinetic trial in children of lead candidate
Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001...
Want to see all releases?
To see all releases including those not listed here, go to our filings and reports.